ArticleInvestigational new drugs2024

Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer.

Shubham Pant et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.